Clinical lymphoma, myeloma & leukemia · 2026
A Single-center Retrospective Study of MIAD ± R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yuedan, Cui Qu, Qian Jun, Bai Xueyan, Xing Ruixian, Liu Jing, Liu Qing, Wu Yuchen, Lai Wenyuan, Han Huixiu, Liu Yuanbo, Sun Xuefei, Fu Lin
Аннотация
BACKGROUND: The optimal induction therapy for primary central nervous system lymphoma (PCNSL) has not been well-established. The aim of this study was to evaluate clinical efficacy and safety of the MIAD ± R (methotrexate, ifosfamide, cytarabine, dexamethasone, and with/without rituximab) regimen in patients with newly diagnosed PCNSL.
PATIENTS AND METHODS: In this monocentric retrospective study, we collected clinical data from PCNSL patients treated with MIAD ± R to report our institutional experience with this regimen in real-world practice. Patient demographic and clinical data were analyzed using descriptive statistics. The Kaplan-Meier curves were employed to estimate overall survival (OS) and progression-free survival (PFS).
RESULTS: Eighty-one patients were consecutively included with a median follow-up of 23.1 months (95% confidence interval [CI], 17.6-28.6), among which, 50 (61.7%) patients achieved complete remission (CR), 25 (30.9%) achieved partial remission (PR), 3 (3.7%) had stable disease (SD) and 3 (3.7%) had progression of disease (PD). The objective response rate (ORR) was 92.6%. The median PFS was 11.8 months (95% CI, 4.9-18.7), and the 1-year PFS rate was 49.2%. The median overall survival (OS) was not reached; the 1-year OS rate was 93.5%. Adverse events (AEs) were manageable with standard supportive care; neutropenia (66.7%) and alanine aminotransferase/aspartate aminotransferase elevations (63%) were the most common events. No treatment related death was recorded.
CONCLUSIONS: The MIAD ± R regimen is a viable treatment option for newly diagnosed PCNSL with favorable efficacy and an acceptable safety profile. Further prospective trials are warranted to verify its value in the first-line standard of treatment in PCNSL.
PATIENTS AND METHODS: In this monocentric retrospective study, we collected clinical data from PCNSL patients treated with MIAD ± R to report our institutional experience with this regimen in real-world practice. Patient demographic and clinical data were analyzed using descriptive statistics. The Kaplan-Meier curves were employed to estimate overall survival (OS) and progression-free survival (PFS).
RESULTS: Eighty-one patients were consecutively included with a median follow-up of 23.1 months (95% confidence interval [CI], 17.6-28.6), among which, 50 (61.7%) patients achieved complete remission (CR), 25 (30.9%) achieved partial remission (PR), 3 (3.7%) had stable disease (SD) and 3 (3.7%) had progression of disease (PD). The objective response rate (ORR) was 92.6%. The median PFS was 11.8 months (95% CI, 4.9-18.7), and the 1-year PFS rate was 49.2%. The median overall survival (OS) was not reached; the 1-year OS rate was 93.5%. Adverse events (AEs) were manageable with standard supportive care; neutropenia (66.7%) and alanine aminotransferase/aspartate aminotransferase elevations (63%) were the most common events. No treatment related death was recorded.
CONCLUSIONS: The MIAD ± R regimen is a viable treatment option for newly diagnosed PCNSL with favorable efficacy and an acceptable safety profile. Further prospective trials are warranted to verify its value in the first-line standard of treatment in PCNSL.